With the increasing prevalence of type 2 diabetes and its complications throughout the world, there is a need for efficient and safe therapeutic strategies. The dipeptidyl peptidase-4 (DPP-4) inhibitors have become important oral glucose lowering drugs for the management of patients with type 2 diabetes. All DPP-4-inhibitors act on the incre - tin system to lower hyperglycemia, have a similar safety profile, are well tolerated, do not cause significant weight gain and have a relatively low risk of hypoglycemia. However, there are clinical differences among the four agents, sitagliptin, vildagliptin, saxagliptin, and linagliptin which are currently approved by the US Food and Drug Admi - nistration or the European Medicines Agency. This review article discusses similarities and differences in efficacy, safety and tolerability of these four DPP-4-inhibitors.
- MeSH
- diabetes mellitus 2. typu * farmakoterapie metabolismus MeSH
- glukagonu podobný peptid 1 * účinky léků MeSH
- hodnocení léčiv MeSH
- hyperglykemie * farmakoterapie MeSH
- hypoglykemie chemicky indukované prevence a kontrola MeSH
- inhibitory dipeptidylpeptidasy 4 * aplikace a dávkování farmakologie metabolismus MeSH
- inkretiny * metabolismus terapeutické užití MeSH
- lidé MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
